Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
argenx SE (ARGX) is trading at $955.32, up 1.00% on the day. Its market value of $59.77B makes it the 269th largest of the 300 companies we follow.
Over the past 52 weeks it has traded between $661.85 and $1,072.75, so it sits 10.9% below the top of that range. Holders are ahead 30.9% over twelve months, and up 12.1% across the last three months.
On the chart it holds above both the 50-day ($944.92) and 200-day ($848.88) moving averages; RSI is 43, and the last 30 sessions moved at roughly 51% annualized volatility.
For the quarter ended Jun 2026 it reported $1.52B in revenue, up 59.6% from a year earlier, with $472.00M of net profit (a 32.8% margin).
Valuation works out to 36.4 times trailing earnings. The median for its industry group is 34.1.
20 analysts follow the stock and the average call is "buy". The mean target, $1,178.42, sits 23.4% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
argenx is a Belgian-Dutch biotech that sells Vyvgart, a treatment for the autoimmune condition myasthenia gravis, and is testing it in other diseases.
What tends to move it. New approved uses for Vyvgart and clinical trial readouts are the main catalysts. It does not yet earn a steady profit.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -5.2% | Bearish |
| Price vs 50-day average | +1.1% | Bullish |
| Price vs 200-day average | +12.5% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 42.7 | Bearish |
| MACD (12,26,9) | 3.05 | Bearish |
| Bollinger band position | 8% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 2:00 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q2, ended Jun 2026
Quarter 2025/FY
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 85th percentile, 5-year average -75.3x
#2294 of 2977 stocks by PE (1 = cheapest)
Around its usual level · 56th percentile, 5-year average 7.3x
#4643 of 5304 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 7th percentile, 5-year average 34.8x
#4466 of 5143 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: +$6.60M (11 inflow days, 9 outflow days).
$955.32 is the latest print for ARGX, a move of +1.00% against yesterday's close of $945.82. Today's low and high so far: $944.21 and $965.27.
Equity value comes to $59.77B at the current price. By that measure it is number 269 of the 300 names in our coverage.
Buyers pay 36.4 times the last twelve months of profit (EPS $19.57).
The year's floor is $661.85 and the ceiling $1,072.75. Shares are 10.9% away from that ceiling.
Our data shows no dividend paid by argenx SE over the trailing twelve months.
Of 20 analysts, 95% say buy, 5% hold and 0% sell. Price targets average $1,178.42, with the most cautious at $932.00 and the most optimistic at $1,415.00.
argenx is a Belgian-Dutch biotech that sells Vyvgart, a treatment for the autoimmune condition myasthenia gravis, and is testing it in other diseases.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.